Skip to main content
. 2021 Sep 24;3(12 Suppl):S209–S217. doi: 10.1016/j.cjco.2021.09.015

Table 5.

Study details for trial leads, sites, and authorship of included implantable cardioverter–defibrillator randomized controlled trials

Parameter Frequency Parameter Frequency
Trial origin Trial enrollment sites
 North America 4 (80)  North America 4 (40)
 Europe 1 (20)  Europe 3 (30)
 Australia 0  Australia 2 (20)
 Asia 0  Asia 1 (10)
 Africa 0  Africa 0
 South America 0  South America 0
First author by sex Corresponding author by sex
 Male 2 (40)  Male 2 (40)
 Female 3 (60)  Female 3 (60)
First author by race Corresponding author by race
 White 4 (80)  White 4 (80)
 Black 0  Black 0
 Hispanic 1 (20)  Hispanic 0
 Asian 0  Asian 1 (20)
 Southeast Asian 0  Southeast Asian 0
 Other 0  Other 0
First author by site Corresponding author by site
 North America 4 (80)  North America 4 (80)
 Europe 1 (20)  Europe 1 (20)
 Australia 0  Australia 0
 Asia 0  Asia 0
 Africa 0  Africa 0
 South America 0  South America 0
Funding recipient by sex Funding sponsor by trial
 Male 5 (100)  Industry 3 (50)
 Female 0  Peer-reviewed 3 (50)
Funding recipient by race Funding recipient by site
 White 4 (80)  North America 4 (80)
 Black 0  Europe 1 (20)
 Hispanic 0  Australia 0
 Asian 1 (20)  Asia 0
 Southeast Asian 0  Africa 0
 Other 0  South America 0

Values are n (%).

Funding recipient/s were those acknowledged from the article, when possible, or was considered to be the corresponding study lead as listed at clinicaltrials.gov, if not otherwise stated.

One study, Tang et al.,17 reported funding from both sources.